NEWPORT BEACH, California (August 13, 2024) – CureDuchenne, a global nonprofit dedicated to funding and finding a cure for Duchenne muscular dystrophy, is excited to announce the inaugural Ladies Luncheon […]
Letter to the Duchenne Community – INSPIRE DUCHENNE update Dear Duchenne Community, We are writing to share an important update on INSPIRE DUCHENNE, our Phase 1/2 clinical trial of SGT-003 for […]
Avidity Biosciences, which received early funding from CureDuchenne, announced positive initial data from their EXPLORE44 Trial for individuals with Duchenne amenable to skipping exon 44. Their experimental exon-skipping agent, AOC […]
Annual Event Features an Afternoon of Fashion and Fun to Raise Funds to Help Find a Cure for Duchenne Muscular Dystrophy AUSTIN, Texas (August 5, 2024) – CureDuchenne, a leading […]
Study Co-Funded by CureDuchenne and cTAP Highlights Need for More Specific Enrollment Criteria That Could Increase Patient Participation and Drive More Comprehensive Therapeutic Evaluation CAMBRIDGE, Mass., July 24, 2024 – […]
Link to press release We are thrilled to share the latest data from RegenXBio’s microdystrophin gene therapy, AFFINITY DUCHENNE®. RGX-202 is a one-time gene therapy for Duchenne designed to deliver […]
Pfizer Duchenne Program Discontinuation: Pfizer has officially decided to discontinue their microdystrophin gene therapy program for Duchenne, after the sad announcement last month that the Phase 3 trial failed to […]
First nonsteroidal treatment approved for patients six years of age and older with DMD regardless of genetic mutation now available in the U.S. ITF also announces the launch of ITF […]
READ THE FULL PRESS RELEASE HERE Introduction The journey towards finding effective treatments for Duchenne Muscular Dystrophy (DMD) has been marked by significant milestones. However, recent findings indicate that we […]
